The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial.
Andrea BotticelliSilvia MeziGiulia PomatiPaolo SciattellaBruna CerbelliMichela RobertoGiulia MammoneAlessio CirilloAlessandra CassanoCarmela Di DioAlessio CortelliniLaura PizzutiGraziana RonzinoMassimiliano SalatiPatrizia ViciAntonella PolimeniMarco Carlo MerlanoMarianna NutiPaolo MarchettiPublished in: Vaccines (2020)
nivolumab in R/M HNSCC is burdened with a high early progression rate. Previous wide neck dissection and high dose radiotherapy may compromise the efficacy of nivolumab, distorting the anatomy of the local lymphatic system and hindering the priming of immune response.